ACR Congress Review 2019
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Highlights from <strong>ACR</strong> <strong>2019</strong><br />
During the <strong>ACR</strong> <strong>2019</strong> annual meeting, many presentations and posters reported on cytokine signalling<br />
and related drugs. This document reviews the highlights.<br />
NOVEL TREATMENTS – Clinical Trials<br />
Filgotinib<br />
Filgotinib Phase 3 studies in RA patients – FINCH1 and FINCH3<br />
Combe and colleagues presented the primary outcome results from the Phase 3, double-blind,<br />
active- and placebo-controlled FINCH1 study evaluating filgotinib versus adalimumab or placebo in<br />
patients with active RA and an inadequate response to MTX. The study randomised 1,759 patients, of<br />
whom 1,755 received study drug and were analysed (filgotinib 200 mg QD, n=475; filgotinib 100 mg QD,<br />
n=480; adalimumab 40 mg Q2W, n=325; placebo, n=475). At Week 12, significantly more patients in the<br />
filgotinib 200 mg and 100 mg arms achieved an <strong>ACR</strong>20 response compared with placebo (76.6%,<br />
69.8% and 49.9%, respectively). Similarly, compared to placebo, more patients receiving filgotinib<br />
achieved <strong>ACR</strong>50 and <strong>ACR</strong>70 responses, DAS28-CRP scores ≤3.2 and
Change language